Payment overview · 2025
General Payments
$14,079.14
247 reported records · 38 companies
Healthcare provider profile · identity verified
Mark B Silverman, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FARMINGTON HILLS, MI · NPI 1336147958
Verified facts
What the public records show
CMS Open Payments records show Mark B Silverman, DO received $14,079.14 in general payments during 2025 across 247 reported records.
Biogen, Inc. accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Vumerity, Zeposia.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Zeposia by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ingrezza by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $6,255.10 | 44.4% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $3,804.61 | 27.0% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $419.01 | 3.0% | 60 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $298.46 | 2.1% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $295.75 | 2.1% | 16 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $291.73 | 2.1% | 12 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $270.51 | 1.9% | 12 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $243.21 | 1.7% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $234.90 | 1.7% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $182.91 | 1.3% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $173.09 | 1.2% | 6 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $162.89 | 1.2% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.06 | 1.1% | 7 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $104.57 | 0.7% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $103.37 | 0.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $101.24 | 0.7% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $99.58 | 0.7% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.33 | 0.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.54 | 0.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $73.56 | 0.5% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $67.84 | 0.5% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.78 | 0.5% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $57.94 | 0.4% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.08 | 0.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.51 | 0.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.43 | 0.3% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $45.78 | 0.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.77 | 0.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.12 | 0.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$30.13 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.94 | 0.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.67 | 0.2% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $22.70 | 0.2% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $20.81 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.91 | 0.1% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $17.25 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.43 | 0.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$14.63 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,908.00 | 7 |
| Food and Beverage | $4,305.56 | 235 |
| Consulting Fee | $824.00 | 3 |
| Travel and Lodging | $41.58 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $5,861.41 | 6 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $3,967.50 | 27 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $419.01 | 60 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $399.41 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $298.46 | 12 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $270.51 | 12 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $243.21 | 7 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $234.90 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $222.29 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $210.66 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $173.09 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $152.06 | 7 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $104.57 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $103.37 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $101.31 | 6 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $99.58 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $81.24 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $75.33 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $74.54 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $67.84 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $67.78 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $62.58 | 4 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $50.51 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $35.75 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $35.75 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 683 | 174 |
| Memantine Hcl | Memantine Hcl | 261 | 68 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 216 | 55 |
| Levetiracetam | Levetiracetam | 213 | 51 |
| Gabapentin | Gabapentin | 198 | 67 |
| Primidone | Primidone | 152 | 47 |
| Pregabalin | Pregabalin | 131 | 47 |
| Lacosamide | Lacosamide | 97 | 21 |
| Galantamine Er | Galantamine Hbr | 93 | 20 |
| Sertraline Hcl | Sertraline Hcl | 83 | 18 |
| Memantine Hcl Er | Memantine Hcl | 76 | 17 |
| Topiramate | Topiramate | 75 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 18 |
| Trazodone Hcl | Trazodone Hcl | 67 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 16 |
| Lamotrigine | Lamotrigine | 62 | 15 |
| Diazepam | Diazepam | 60 | 54 |
| Baclofen | Baclofen | 57 | 15 |
| Carbamazepine Er | Carbamazepine | 55 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Austedo | Deutetrabenazine | 27 | suppressed |
| Dalfampridine Er | Dalfampridine | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Ingrezza | Valbenazine Tosylate | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Vumerity | Diroximel Fumarate | 18 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 17 | suppressed |
| Aubagio | Teriflunomide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Fingolimod | Fingolimod Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Vimpat | Lacosamide | 14 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Depakote Er | Divalproex Sodium | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,079.14 · 247 records | Biogen, Inc. | AJOVY, AMPYRA, AMVUTTRA, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Bafiertam, Briviact, EPIDIOLEX, FYCOMPA, Fintepla, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KEVEYIS, KISUNLA, Leqembi, Mavenclad, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PEMGARDA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error